TLT (30year US Treasury Bond)ETF.

st lois fed 2011

There is a gap in this chart simple because at one point they stopped issuing 30 year bonds, they did not think they needed that maturity given the budget surpluses. Hard to believe now.

The TLT does pretty much the same but on price . not yield, so it is the inverse.

tlt 2011

I did not anticipate the jump to 110 on the right shoulder (see previous comments). Ironically the drop from there coincides almost perfectly with the Feds announcement of QE2, not exactly what they had in mind! So here we are at about 90 (4.24% yield), about the average of the past eight years. But it certainly looks like the peak at around 2.30% is behind us. If the head and shoulder pattern is correct the TLT should drop to at least 70 over the next few years which would equate to roughly 7%. Perhaps a level where interest rates should be anyway.

In Canada the XBB ETF , based on a broader bond index (not shown), has a very distinct wedge like structure to it, suggesting it too is about to turn .

Perhaps it will take the same 34 years for yield to go down as it took for them to go up (1945 to 1980). In that case buying a zero-coupon 30-year bond would be very profitable. But this to me is a little like an “after us the deluge” kind of trade, one that does not logically combine with owning any stock.

SU Suncor / COS Can. Oil Sands

Suncor reported earnings, not surprisingly they were very good, exactly what the chart was suggesting. Here it is;

su 20112 Su 2011

The big charts is like most, 5 up followed by a correction that looks a lot like an incomplete a-b-c. Normal target is in the order of $50 or so in order to get symmetry (c=a) and get to the 50/60% retracement level (see detail chart). The pattern is pretty straightforward with the b as a triangle. (the triangle may be shorter than shown!). The stock at about $42 should therefore have about $8 potential.

Canadian Oil Sands is a different kettle of fish;

cos 2011 l  cos 20112

Notice that in the big picture both stocks look pretty much the same. However short-term COS has not really budged at all of the lows. Perhaps this has yet to happen but nevertheless it raises the caution flag! Last September we already expected the stock to start moving up , see chart below. So far the move is rather anemic which may be telling us something.

cos.un sept 2010

Use stops at around $22.

VRX, Valeant Pharma. Int. What’s in a name?

Biovale and Valeant merged in 2009, much to the chagrin of  the , larger than life, founder Eugene Melnyk . After  sordid allegations of accounting irregularities and lots of negative publicity, courtesy 60 minutes etc. ,  the company needed  to rebrand itself and it chose the merger and name change to achieve that goal. We all know the story of the pig and the hen that decide to merge and go into the business of selling bacon and eggs ; one of the two parties always dies in the process. In this case Mr. Melnyk confidently stated that the “business models of both companies were fundamentally broken” and that he would not want to own the stock four years from now. Half that time has passed, and the stock is up four-fold after announcing (today) another take-over, this time of privately held Swiss Pharma. Sour grapes perhaps? Here are the charts.

vrx 2011 vrx 2011 s

Looking at the Bigchart (still available under the ticker BVF) , it is clear that the stock completed the 5-wave ride up to $90 or so, followed, predictable, by a dramatic drop to about $7 (I already liked it at $16, too early as usual!). The drop appears to be an A-B-C (actually an a-b-c-X-a-b-c). The first logical rebound target is at about $32, than about $50, $58 and $70, wave 4, 50%, 62% and B-wave level respectively. We have no idea which it will be, but it is already possible to count 5 waves up and we have reached a one year target  ($41) at a very astute investment dealer already , which, by the way, has the stock on its Focus List (see elsewhere). We would recommend a very tight stop if you own this. Just remember Juliet’s words to Romeo; “That which we call a rose, by any other name would smell as sweet.”